author-photo

Pei-Ran Ho

Amgen

17

Papers

575

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

2015 Osteoporosis International
Show All
- Source
- Cite
- Save
Citations (47)
A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial

2015 The Journal of Clinical Endocrinology and Metabolism
Show All
- Source
- Cite
- Save
Citations (70)
Traitement par denosumab chez des hommes à masse osseuse basse: résultats à 24 mois de l'étude ADAMO

2015 Revue du Rhumatisme
Show All
- Source
- Cite
- Save
Citations (0)
Treatment Satisfaction in Postmenopausal Women Suboptimally Adherent to Bisphosphonates Who Transitioned to Denosumab Compared With Risedronate or Ibandronate

2015 The Journal of Clinical Endocrinology and Metabolism
Show All
- Source
- Cite
- Save
Citations (16)
In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

2014 Bone Abstracts
Show All
- Source
- Cite
- Save
Citations (0)
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate

2014 Osteoporosis International
Show All
- Source
- Cite
- Save
Citations (40)
Denosumab for the treatment of men with low bone mineral density: 24-month results from the Adamo Trial

2014 Endocrine Reviews
Show All
- Source
- Cite
- Save
Citations (0)
Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.

2014 Journal of Bone and Joint Surgery, American Volume
Show All
- Source
- Cite
- Save
Citations (89)
THU0418 Denosumab Versus Risedronate: Efficacy and Safety in Postmenopausal Women Suboptimally Adherent to Alendronate Therapy in a Randomized Open-Label Study

2013 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

2013 Bone Abstracts
Show All
- Source
- Cite
- Save
Citations (0)